Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study

J Clin Rheumatol. 2022 Dec 1;28(8):420-423. doi: 10.1097/RHU.0000000000001857. Epub 2022 Jun 2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Ankylosis*
  • Antibodies, Monoclonal / adverse effects
  • Antirheumatic Agents* / adverse effects
  • Humans
  • Spondylitis, Ankylosing* / complications
  • Spondylitis, Ankylosing* / diagnosis
  • Spondylitis, Ankylosing* / drug therapy
  • Treatment Outcome

Substances

  • golimumab
  • Antibodies, Monoclonal
  • Antirheumatic Agents